Collegium Pharmaceutical, Inc.: A Leading Innovative Pharmaceutical Company that Warrants Your Attention
Victory Capital Management Inc. recently lowered its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 10.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 114,376 shares of the specialty pharmaceutical company’s stock after selling 13,530 shares during the period. Victory Capital Management Inc. owned about 0.34% of Collegium Pharmaceutical, worth $2,909,000 as of its most recent filing with the SEC.
Headquartered in Stoughton, Massachusetts, Collegium Pharmaceutical is a forward-thinking healthcare firm that focuses on developing and commercializing next-generation abuse-deterrent products targeted towards patients suffering from chronic pain and other disorders. Its latest line of products includes Xtampza ER, Nucynta ER and Nucynta IR, Belbuca and Symproic.
Reports from leading research analysts have been promising for Collieum Pharmacuetical prospects this year. StockNews.com raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Wednesday, May 24th while Needham & Company LLC re-iterated their “buy” rating and set a $35 target price on shares of ColleCtive PharmaCeutical in a research report on Wednesday, April 19th.
Thus far this year alone, CPLL has garnered significant attention particularly among investors despite the ongoing volatile climate in the wake of COVID-19 pandemic concerns and other market headwinds.
The current bullish trends surging its way are likely due to several factors such as increased demand for abuse-deterrent products by healthcare providers and regulators alike; strong financials as reflected by consistent positive cash flows since last year; and a robust product pipeline that is expected to grow in the coming months with several projects currently undergoing clinical trials.
There’s no better time to invest in the pharmaceutical industry, especially for those looking for long-term stability. Despite the current uncertainty, Collegium Pharmaceutical has shown tremendous adaptability and quick thinking which gives it an edge in taking advantage of emerging opportunities while fending off risks inherent in today’s market environment.
Hedge Funds Increase Positions in Collegium Pharmaceutical as Company Develops Next-Generation Abuse-Deterrent Products for Chronic Pain Treatment
Collegium Pharmaceutical, a developer of next-generation abuse-deterrent products for the treatment of chronic pain and other diseases, has seen an increase in buying and selling of its shares by hedge funds. Summit Global Investments raised its stake in the company by 0.4%, Swiss National Bank increased its investment by 1% while Bank of Montreal Can and Price T Rowe Associates upped their positions in Collegium Pharmaceutical considerably. However, news also came to light that CFO Colleen Tupper sold around 31,640 shares of the company’s stock for approximately $752,082.80 on March 15 and executive vice president Scott Dreyer also sold over 13k shares this year. Despite these changes with corporate insiders owning just under 4% of the stock, the firm remains strong with a market cap of $779.54m.
COLL opened at $22.53 on Monday with a PE ratio of -26.20 and beta rate of 0.81, reflecting a sensible degree of volatility that may attract investors seeking new or riskier investments. The results from first-quarter earnings earlier this year revealed earnings per share for the quarter of $1.18, missing analysts’ estimates by two cents as per rival newsletters citing Financial Times data points have shown.
Analysts forecast that Collegium Pharmaceutical will post EPS figures in excess of four times this amount across each fiscal year going forward – potentially making it one to watch for savvy investors able to handle some exposure within portfolio management strategies.